The FDA Oncologic Drugs Advisory Committee (ODAC) voted 8 to 3 in favor of using intravenous infusion of idecabtagene vicleucel (ide-cel; Abecma) for patients with pretreated relapsed/refractory multiple myeloma.

Read More >https://multiplemyeloma.pocn.com/treatment/fda-odac-backs-ide-cel-in-multiple-myeloma-highlighting-karmma-3-trial-results/